Suven granted two more US patents for drugs to treat Alzheimer’s, schizophrenia

Indian CRAMS player Suven Life Sciences Ltd has been granted two new US patents for its class of selective 5-HT compounds for the treatment of disorders associated with neurodegenerative diseases like Alzheimer’s disease, Parkinson and schizophrenia .

Suven received patents numbers US 7,507,835 and US 7,388,024 corresponding to two new chemical entities (NCEs) from the US Patent Office. These two patents are valid till until 2022 & 2024 respectively, Suven said in an official release.

Suven’s patents cover the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and schizophrenia .

Currently, Suven has total of four granted US patents on NCEs.

suven secured its first US product patent no. US 7,297,711 in December 2007. The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by Suven.

In January 2008, Suven announced that the company received its second product Patent number US 7,317,035.  According to the invention ‘035 patent disclosure, the compounds are useful in the treatment of neurodegenarative disorders like Alzheimer’s, Parkinson, Schizophrenia and Huntington’s.

Suven has so far filed 29 product patent applications through PCT covering more than 145 countries, out of which 5 product patents are granted in various countries.

The new patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II, the release stated.

“We are very pleased by the grant of these patents to Suven by US Patent office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $20 billion market potential globally,” said Venkat Jasti, CEO of Suven is quoted as saying.

Last week, Suven Life Sciences announced that the company received first milestone payment from Eli Lilly for drug discovery collaboration in central nervous system (CNS) disorder.

Suven achieved with the identification and selection of a 1st Lead compound to be advanced into Lead Optimization Phase of preclinical development.

Suven entered into drug discovery collaboration with Eli Lilly and Company, USA to jointly discover and develop candidates for the treatment of CNS disorders,in 2008. Under the terms of the agreement Lilly will undertake the clinical development of the selected candidate/s and commercialization globally. Lilly will have the full ownership of the candidates developed under this collaboration while Suven receives ongoing research payments and preclinical milestones.

The contract also provides substantial long-term upside for Suven through potential payments for successful milestones achieved during clinical development and royalties on worldwide sales if new drugs are commercialized.

Hyderabad-based Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing therapies through the use of GPCR targets.
Suven has six internally discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease. Parkinson’s disease and obesity are in addition to developmental candidates in Alzheimer’s disease and schizophrenia.